Wilbanks Smith & Thomas Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$3.38M	Buy	62,412 +4,562	+8%	+$232K	0.09%	133
2023 Q4	$2.97M	Sell	57,850 -102,986	-64%	-$5.41M	0.09%	135
2023 Q3	$9.33M	Sell	160,836 -3,573	-2%	-$219K	0.32%	78
2023 Q2	$10.5M	Sell	164,409 -7,240	-4%	-$485K	0.35%	71
2023 Q1	$11.9M	Sell	171,649 -950	-0.6%	-$67K	0.41%	64
2022 Q4	$12.4M	Buy	172,599 +1,778	+1%	+$134K	0.47%	54
2022 Q3	$12.1M	Buy	170,821 +3,295	+2%	+$239K	0.52%	46
2022 Q2	$12.9M	Buy	167,526 +635	+0.4%	+$48.4K	0.54%	38
2022 Q1	$12.5M	Buy	166,891 +4,684	+3%	+$315K	0.5%	43
2021 Q4	$10.1M	Sell	162,207 -34,759	-18%	-$2.04M	0.35%	69
2021 Q3	$11.7M	Buy	196,966 +9,551	+5%	+$629K	0.46%	53
2021 Q2	$12.5M	Buy	187,415 +12,752	+7%	+$832K	0.49%	41
2021 Q1	$11M	Buy	174,663 +9,332	+6%	+$581K	0.48%	43
2020 Q4	$10.3M	Buy	165,331 +10,971	+7%	+$675K	0.48%	45
2020 Q3	$9.31M	Buy	154,360 +7,649	+5%	+$460K	0.5%	40
2020 Q2	$8.63M	Buy	146,711 +8,072	+6%	+$483K	0.52%	40
2020 Q1	$7.73M	Buy	138,639 +15,642	+13%	+$956K	0.57%	34
2019 Q4	$7.89M	Buy	122,997 +5,860	+5%	+$336K	0.47%	42
2019 Q3	$5.94M	Buy	117,137 +4,943	+4%	+$232K	0.38%	59
2019 Q2	$5.09M	Buy	112,194 +6,668	+6%	+$311K	0.33%	69
2019 Q1	$5.04M	Buy	105,526 +15,182	+17%	+$756K	0.33%	71
2018 Q4	$4.7M	Buy	90,344 +1,722	+2%	+$92.5K	0.32%	58
2018 Q3	$5.5M	Sell	88,622 -3,018	-3%	-$179K	0.33%	60
2018 Q2	$5.07M	Buy	91,640 +2,227	+2%	+$120K	0.41%	52
2018 Q1	$5.66M	Sell	89,413 -106	-0.1%	-$6.82K	0.45%	43
2017 Q4	$5.49M	Buy	89,519 +4,355	+5%	+$272K	0.43%	44
2017 Q3	$5.43M	Buy	85,164 +1,931	+2%	+$113K	0.46%	44
2017 Q2	$4.64M	Sell	83,233 -291	-0.3%	-$15.8K	0.41%	49
2017 Q1	$4.54M	Buy	83,524 +10,478	+14%	+$575K	0.39%	51
2016 Q4	$4.27M	Buy	73,046 +38,257	+110%	+$2.09M	0.38%	48
2016 Q3	$1.88M	Sell	34,789 -2,626	-7%	-$169K	0.18%	91
2016 Q2	$2.75M	Sell	37,415 -1,182	-3%	-$83.5K	0.29%	67
2016 Q1	$2.47M	Buy	38,597 +1,269	+3%	+$80K	0.3%	66
2015 Q4	$2.57M	Buy	37,328 +3,020	+9%	+$200K	0.25%	68
2015 Q3	$2.03M	Sell	34,308 -2,399	-7%	-$152K	0.29%	64
2015 Q2	$2.44M	Sell	36,707 -1,319	-3%	-$86.9K	0.24%	65
2015 Q1	$2.45M	Sell	38,026 -2,323	-6%	-$145K	0.24%	71
2014 Q4	$2.38M	Buy	40,349 +34	+0.1%	+$1.92K	0.24%	71
2014 Q3	$2.06M	Buy	40,315 +1,676	+4%	+$83.7K	0.22%	76
2014 Q2	$1.87M	Buy	38,639 +72	+0.2%	+$3.55K	0.2%	87
2014 Q1	$2M	Sell	38,567 -575	-1%	-$30.6K	0.23%	77
2013 Q4	$2.08M	Sell	39,142 -3,097	-7%	-$158K	0.25%	68
2013 Q3	$1.96M	Sell	42,239 -677	-2%	-$29.7K	0.26%	68
2013 Q2	$1.92M	Buy	+42,916	New	+$1.86M	0.29%	62

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's BMY Position: Q1 2024 in Review

Wilbanks Smith & Thomas Asset Management increased its Bristol-Myers Squibb (BMY) stake by 7.9% in Q1 2024, buying an estimated $232K and bringing the position to 62,412 shares worth $3.38M. The position accounts for 0.09% of the portfolio, ranked #133.

Wilbanks Smith & Thomas Asset Management first reported a position in BMY in Q2 2013 and has held it in 44 quarters since. The position peaked at $12.9M in Q2 2022. 2,332 funds tracked by Wall St. Rank hold BMY as of Q1 2024.

Wilbanks Smith & Thomas Asset Management held 62,412 shares of Bristol-Myers Squibb worth $3.38M as of Q1 2024.
Wilbanks Smith & Thomas Asset Management bought 4,562 Bristol-Myers Squibb shares in Q1 2024, an estimated $232K.
Bristol-Myers Squibb made up 0.09% of Wilbanks Smith & Thomas Asset Management's portfolio in Q1 2024, its #133 holding.
Wilbanks Smith & Thomas Asset Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 44 quarters since.
Wilbanks Smith & Thomas Asset Management's Bristol-Myers Squibb position peaked at $12.9M in Q2 2022.
2,332 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2024.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q1 2024, filed 7 May 2024.